Review Article

You have full text access to this OnlineOpen article

Pulmonary neuroendocrine/carcinoid tumors

A review article

  1. Erin M. Bertino MD1,
  2. Patricia D. Confer BS, CTR2,
  3. Jorge E. Colonna MD3,
  4. Patrick Ross MD, PhD4,
  5. Gregory A. Otterson MD1,†,*

Article first published online: 26 JUN 2009

DOI: 10.1002/cncr.24498

Issue

Cancer

Cancer

Volume 115, Issue 19, pages 4434–4441, 1 October 2009

Additional Information

How to Cite

Bertino, E. M., Confer, P. D., Colonna, J. E., Ross, P. and Otterson, G. A. (2009), Pulmonary neuroendocrine/carcinoid tumors. Cancer, 115: 4434–4441. doi: 10.1002/cncr.24498

Author Information

  1. 1

    Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio

  2. 2

    Arthur G. James and Richard J. Solove Cancer Hospital and Research Institute, Cancer Registry, Columbus, Ohio

  3. 3

    Department of Pathology, Ohio State University College of Medicine, Columbus, Ohio

  4. 4

    Department of Surgery, Division of Thoracic Surgery, Ohio State University College of Medicine, Columbus, Ohio

  1. †

    Fax: (614) 293-7529

*Department of Internal Medicine, Ohio State University College of Medicine, 320 West 10th Avenue, Columbus, OH 43210

Publication History

  1. Issue published online: 17 SEP 2009
  2. Article first published online: 26 JUN 2009
  3. Manuscript Accepted: 19 FEB 2009
  4. Manuscript Revised: 2 DEC 2008
  5. Manuscript Received: 10 OCT 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (218K)

Keywords:

  • carcinoid;
  • malignancy;
  • lung cancer;
  • pulmonary;
  • neuroendocrine

This article reviewed the recent literature regarding pulmonary carcinoid/well-differentiated neuroendocrine tumors. Clinical, pathologic, and radiographic evaluations were discussed as well as treatment strategies.

Abstract

Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well-differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors. Cancer 2009. © 2009 American Cancer Society.

View Full Article (HTML) Get PDF (218K)